

Title (en)

Methods and compositions for treating prostate cancer

Title (de)

Verfahren und Zusammensetzungen zur Behandlung von Prostatakrebs

Title (fr)

Procédés et compositions pour le traitement du cancer de la prostate

Publication

**EP 2725103 A2 20140430 (EN)**

Application

**EP 14152478 A 20121114**

Priority

- US 201161629135 P 20111114
- EP 12192666 A 20121114

Abstract (en)

The invention relates to a millimeter-scale drug delivery device (DDD) comprising a biodegradable polymeric matrix and an RNAi (RNA interference) agent that targets BMI1 polycomb ring finger oncogene (BMI-1), within said biodegradable polymeric matrix, for treatment of prostate cancer by regional and prolonged release.

IPC 8 full level

**C12N 15/113** (2010.01); **A61K 9/00** (2006.01); **A61K 9/70** (2006.01); **A61K 31/713** (2006.01); **A61K 47/34** (2006.01)

CPC (source: EP US)

**A61B 8/4444** (2013.01 - US); **A61B 10/0241** (2013.01 - EP US); **A61K 9/0024** (2013.01 - EP US); **A61K 9/0034** (2013.01 - US); **A61K 9/7007** (2013.01 - EP US); **A61K 31/713** (2013.01 - EP US); **A61K 45/06** (2013.01 - US); **A61K 47/10** (2013.01 - US); **A61K 47/26** (2013.01 - US); **A61K 47/32** (2013.01 - US); **A61K 47/34** (2013.01 - US); **A61N 5/1001** (2013.01 - US); **A61N 5/1007** (2013.01 - US); **C12N 15/111** (2013.01 - EP US); **C12N 15/113** (2013.01 - EP US); **C12N 15/1135** (2013.01 - US); **C12N 15/1138** (2013.01 - EP US); **C12N 2310/111** (2013.01 - US); **C12N 2310/14** (2013.01 - EP US); **C12N 2310/3145** (2013.01 - US); **C12N 2310/32** (2013.01 - US); **C12N 2310/321** (2013.01 - US); **C12N 2310/351** (2013.01 - US); **C12N 2310/3513** (2013.01 - US); **C12N 2310/3515** (2013.01 - US); **C12N 2320/31** (2013.01 - EP US); **C12N 2320/32** (2013.01 - EP US)

Citation (applicant)

- US 2008124370 A1 20080529 - MARX JEFFREY C [US]
- US 2011195123 A1 20110811 - SHEMI AMOTZ [IL]
- US 2009124569 A1 20090514 - BERGAN RAYMOND C [US], et al
- WO 2010086849 A1 20100805 - SILENSEED LTD [IL], et al
- ALSHAMSAN ET AL., STAT3 SILENCING IN DENDRITIC CELLS BY SIRNA POLYPLEXES ENCAPSULATED IN PLGA NANOPARTICLES FOR THE MODULATION OF ANTICANCER IMMUNE RESPONSE, MOLECULAR PHARMACEUTICS, vol. 7, no. 5, 2010, pages 1643 - 1654
- SONG ET AL., CANCER SCI, vol. 101, 2010, pages 1754 - 1760
- MAKADIA; SIEGEL: "Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier", POLYMERS, vol. 3, 2011, pages 1377 - 1397
- RONNIE ORTIZ ET AL., THE AAPS JOURNAL, vol. 9, no. 2, 2007, pages 27
- OLIVIER TREDAN ET AL., J NATL CANCER INST, vol. 99, 2007, pages 1441 - 54
- PATRAWALA ET AL., ONCOGENE, vol. 25, 2006, pages 1696 - 1708
- OLIVER ET AL., JOURNAL OF CELL SCIENCE, vol. 92, 1989, pages 513 - 519
- GUO ET AL.: "Molecular Cancer Therapeutics", MOL CANCER THER., 6 November 2012 (2012-11-06)
- TERRONE ET AL., BIOCHEMISTRY, vol. 42, no. 47, 2 December 2003 (2003-12-02), pages 13787 - 99
- MAGZOUN ET AL., BIOCHIM BIOPHYS ACTA, vol. 1512, no. 1, 2 May 2001 (2001-05-02), pages 77 - 89
- POOGA ET AL., FASEB J., vol. 12, no. 1, January 1998 (1998-01-01), pages 67 - 77

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

**EP 2592146 A2 20130515; EP 2592146 A3 20130724; EP 2725103 A2 20140430; EP 2725103 A3 20160106; US 2013142875 A1 20130606; US 2015196648 A1 20150716; US 9006199 B2 20150414; US 9764035 B2 20170919**

DOCDB simple family (application)

**EP 12192666 A 20121114; EP 14152478 A 20121114; US 201213676581 A 20121114; US 201514672176 A 20150329**